InnoCare Pharma Limited released its monthly return on movements in securities for the period ended January 31, 2026. The authorized share capital remained at 25,000,000,000 ordinary shares with a par value of USD 0.000002 each, totaling USD 50,000.

The total number of ordinary shares in issue (excluding treasury shares) remained at 1,493,798,235, while treasury shares stood at 2,486,000, resulting in a combined total of 1,496,284,235. The company confirmed that the public float requirement of 25% was satisfied, with no changes in issued or treasury shares during the reporting month.

The second class of shares, which are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, remained at 268,359,717 in total and showed no change from the previous month.

Details of share-based incentive schemes indicate no new issuance of shares in January 2026. The monthly return was submitted by the Chairperson and Executive Director, noting no other movements in shares or treasury shares during the month.